Efalizumab: An overview

Journal of the American Academy of Dermatology

Volumn 49, Issue 2 A, 2003, Pages 98-104

  Leonardi, Craig L ^a,b  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Central Dermatology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EFALIZUMAB; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MONOCLONAL ANTIBODY;

ACCIDENTAL INJURY; ARTHRALGIA; ASTHENIA; BACKACHE; CHILL; CLINICAL TRIAL; DIARRHEA; DISEASE ACTIVITY; DISEASE EXACERBATION; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EPIDERMIS; FEVER; HEADACHE; HERPES SIMPLEX; HISTOPATHOLOGY; HUMAN; INFECTION; INJURY; MYALGIA; NAUSEA; PAIN; PATIENT SATISFACTION; PERIPHERAL EDEMA; PHARYNGITIS; PRIORITY JOURNAL; PRURITUS; PSORIASIS; QUALITY OF LIFE; REVIEW; RHINITIS; SIDE EFFECT; SINUSITIS; SKIN BIOPSY; TERATOGENESIS; THICKNESS; VOMITING;

EID: 0043127027     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0190-9622(03)01141-1     Document Type: Review

References (22)

1. Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002;46:1-23.
2. Gottlieb SL, Gilleaudeau P, Johnson R, Estes L, Woodworth TG, Gottlieb AB, et al. Response of psoriasis to a lymphocyte-selec tive toxin (DAB3891L-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med 1995;15:442-7.
3. Sanders ME, Makgoba MW, Sharrow SO, Stephany D, Springer TA, Young HA, et al. Human memory T lymphocytes express increased levels of three cell adhesion molecules (LFA-3, CD2, and LFA-1) and three other molecules (UCHL1, CDw29, and Pgp-1) and have enhanced IFN-γ production. J Immunol 1986;140:1401-7.
4. Nickoloff BJ, Mitra RS, Green J, Zheng X-G, Shimizu Y, Thompson C, et al. Accessory cell function of keratinocytes for superantigens. J Immunol 1993;150:2148-59.
5. Grakoui A, Bromley SK, Sumen C, Davis MM, Shaw AS, Allen PM, et al. The immunological synapse: A molecular machine controlling T cell activation. Science 1999;285:221-7.
6. Van Seventer GA, Shimizu Y, Horgan KJ, Ginter Luce GE, Webb D, Shaw S. Remote T cell costimulation via LFA-1/ICAM-1 and CD2/LFA-3: demonstration with immobilized ligand/mAb and in monocyte-mediated costimulation. Eur J Immunol 1991;21:1711.
7. Werther WA, Gonzalez TN, O'Connor SJ, McCabe S, Chan B, Hotaling T, et al. Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1. J Immunol 1996;157:4986-95.
8. Krueger J, Gottlieb A, Miller B, Dedrick R, Garovoy M, Walicke P. Anti-CD11 a treatment for psoriasis concurrently increases circulating T-cells and decreases plaque T-cells, consistent with inhibition of cutaneous T-cell trafficking. J Invest Dermatol 2000;115:333.
9. Gottlieb A, Krueger JG, Bright R, Ling M, Lebwohl M, Kang S, et al. Effects of administration of a single dose of humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis. J Am Acad Dermatol 2000;42:428-35.
10. Gottlieb AB, Krueger JG, Wittkowski K, Dedrick R, Walicke PA, Garovoy M. Psoriasis as a model for T-cell-mediated disease. Immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody. Arch Dermatol 2002;138:591-600.
11. Papp K, Bissonnette R, Krueger JG, Carey W, Gratton D, Gulliver WP, et al. The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody. J Am Acad Dermatol 2001;45:665-74.
12. Gottlieb AB, Miller B, Chaudhari U, Oh C, Sherr A, Solodkina G, et al. Clinical and histologic effects of subcutaneously administered anti-CD11a (hu1124) in patients with psoriasis. Poster presented at: Annual Meeting of the Society of Investigative Dermatology; May 10-14, 1999; Chicago, IL.
13. Leonardi CL, Gottlieb AB, Miller B, Tashjian D, Pariser D, Shapiro W, et al. Efalizumab (anti-CD11a): results of a 12 week trial of subcutaneous administration in patients with moderate to severe plaque psoriasis. Poster presented at: Annual Meeting American Association of Dermatology; March 2-7, 2001; Washington, DC.
14. Menter A, Bissonnette R, Gottlieb AB, Goffe B, Beutner KR, Dunlap R, et al. Subcutaneous efalizumab (anti-CD11a) provides rapid clinical response in patients with moderate to severe plaque psoriasis. Poster presented at: 60th Annual Meeting of the American Academy of Dermatology; February 22-27, 2002; New Orleans, LA.
15. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine use. Clin Exp Dermatol 1994;19:210-6.
16. Gottlieb AB, Papp KA, Lynde CW, Carey W, Powers J, Rist TE, et al. Subcutaneous efalizumab (anti-CD11a) is effective in the treatment of moderate to severe plaque psoriasis: pooled results of 2 phase III clinical trials. Poster presented at: 60th Annual Meeting of the American Academy of Dermatology; February 22-27, 2002; New Orleans, LA.
17. Menter A, Bissonnette R, Gottlieb AB, Goffe B, Beutner KR, Dunlap R, et al. Subcutaneous efalizumab (anti-CD11a) provides rapid clinical response in patients with moderate to severe plaque psoriasis. Poster presented at: 60th Annual Meeting of the American Academy of Dermatology; February 22-27, 2002; New Orleans, LA.
18. Lebwohl M, Papp KA, Tyring S, Miller JL, Bissonnette R, Walicke P, et al. Continued treatment with subcutaneous efalizumab is safe: pooled results from two phase III trials. Poster presented at: American Academy of Dermatology; July 31-August 4, 2002; New York, NY.
19. Neoral [package insert]. Montvale, NJ: Medical Economics Company, Inc; 2002.
20. Boyd A, Menter A. Erythrodermic psoriasis. J Am Acad Dermatol 1989;21:985-91.
21. Papp KA, Gulliver WP, Monroe E, Shrum J, Huerter CJ, Garovoy M, et al. Retreatment of moderate to severe psoriasis with subcutaneous efalizumab (anti-CD11a): results from an open-label study. Poster presented at: 60th Annual Meeting of the American Academy of Dermatology; February 22-27, 2002; New Orleans, LA.
22. Tristani-Firouzi P, Krueger GG. Efficacy and safety of treatment modalities for psoriasis. Cutis 1998;61:11-21.